Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

09 July 2023 : Clinical Research  

Dysregulation of Inflammation, Oxidative Stress, and Glucose Metabolism-Related Genes and miRNAs in Visceral Adipose Tissue of Women with Type 2 Diabetes Mellitus

Adam Wróblewski ORCID logo1ABCDEF*, Justyna Strycharz ORCID logo1ABCDEF, Katarzyna Oszajca ORCID logo1CE, Piotr Czarny ORCID logo1E, Ewa Świderska ORCID logo1BEF, Tomasz Matyjas2EF, Andrzej Zieleniak ORCID logo3CE, Monika Rucińska2EF, Lech Pomorski ORCID logo2E, Józef Drzewoski ORCID logo4EG, Agnieszka Śliwińska ORCID logo5AEG, Janusz Szemraj ORCID logo1AEG

DOI: 10.12659/MSM.939299

Med Sci Monit 2023; 29:e939299

Supplementary Table 1 Characteristics of 52 study participants. Data is presented as median with an interquartile range, while differences among 3 study groups were evaluated with Kruskal-Wallis one-way analysis of variance (ANOVA) with Dunn’s post hoc test. Study groups were as follows: NGM (normal glucose metabolism), IFG (impaired fasting glucose) and T2DM (diabetic).

Sub.NGM (11 F/9 M)IFG (11 F/6 M)T2DM (12 F/3 M)
Age (years)A65 (60.5, 71)66 (63, 77)66 (62, 72)
F66 (61, 72)66 (63, 77)65.5 (63, 69)
M65 (60, 71)67.5 (60, 80)72 (62, 77)
FPG [mmol/L]A87.48 (81.54, 92.61)107.46 (104.58, 111.42) ()*** 142.56 (127.26, 150.66) ()***
F87.67 (85.68, 92.7)107.46 (101.34, 111.6) ()* 138.42 (128.57, 146.97) ()***
M84.24 (71.1, 92.52)107.32 (106.92, 110.34) ()** 182.7 (100.44, 343.98) ()*
FI [pmol/L]A4.41 (3.26, 9.39)8.74 (5.80, 13.80)20.53 (18.70, 21.28) ()***
F5.37 (4.09, 10.37)9.59 (5.20, 13.80)19.93 (18.24, 21.16) (), ()*
M3.79 (2.55, 4.64)8.04 (6.71, 24.90)
HOMA-IRA1.01 (0.64, 2.14)2.31 (1.60, 3.67) ()* 3.71 (2.26, 5.79) ()**
F1.22 (0.79, 2.37)2.54 (1.58, 3.67)4.50 (2.65, 6.39) ()*
M0.79 (0.45, 1.05)2.13 (1.83, 6.20)
HbA1c [%]A5.5 (5.35, 5.6)5.8 (5.7, 5.9) ()*** 6.7 (6.0, 7.0) (), ()***
F5.5 (5.4, 5.6)5.9 (5.7, 5.9) ()* 6.5 (6.05, 6.9) (), ()***
M5.5 (5.2, 5.5)5.75 (5.7, 5.8) ()* 6.7 (5.9, 9.1) ()**
TC [mmol/L]A4.54 (4.01, 5.19)3.62 (2.9, 4.1) ()* 4.84 (2.89, 5.39)
F4.82 (4.27, 5.39)3.95 (3.27, 5.04)4.85 (2.92, 5.71)
M4.35 (3.50, 4.98)2.69 (2.20, 3.80)4.72 (2.87, 5.39)
LDL-C [mmol/L]A2.9 (2.35. 3.54)2.02 (1.31. 2.5) ()* 2.78 (1.2. 3.43)
F3.11 (2.64, 3.75)2.22 (1.51, 3.11)2.7 (1.03, 3.52)
M2.81 (2.00, 3.03)1.14 (0.89, 2.20)2.93 (1.22, 3.40)
HDL-C [mmol/L]A1.16 (1.02, 1.29)1.07 (0.96, 1.45)1.19 (1.03, 1.29)
F1.18 (1.10, 1.29)1.15 (1.05, 1.60)1.19 (1.07, 1.25)
M1.06 (0.97, 1.28)1.01 (0.91, 1.16)1.29 (0.67, 1.61)
TG [mmol/L]A1.13 (1.03, 1.66)1.11 (0.72, 1.32)1.65 (1.24, 2.2) ()
F1.08 (1.01, 1.72)1.11 (0.85, 1.42)1.76 (1.25, 2.26) ()
M1.49 (1.04, 1.63)0.94 (0.69, 1.32)1.43 (0.79, 1.86)
TG-HDLA2.52 (2.0, 2.82)1.95 (1.34, 2.64)3.20 (2.39, 4.27) ()
F2.14 (1.79, 2. 62)1.95 (1.34, 2.64)3.35 (2.58, 4.25) ()
M2.59 (2.51, 2.83)2.17 (1.32, 3.15)2.65 (1.40, 4.89)
Body mass [kg]A74.5 (68, 84)75 (67, 93)77 (70, 89)
F72 (67, 80)72 (64, 88)72 (70, 82.5)
M83 (75, 100)88 (75, 98)90 (77, 90)
BMI [kg/m]A27.48 (25.79, 31.78)27.89 (25.64, 30.99)30.84 (27.1, 33.91)
F27.51 (25.85, 32.00)27.89 (25.00, 32.72)30.31 (27.22, 34.50)
M27.44 (25.73, 31.56)27.07 (25.95, 30.86)31.14 (24.86, 31.14)
Waist circumference [cm]A
F91 (88, 102)95 (84, 102)101.5 (97.5, 109.5)
M104 (102, 105)102.5 (90, 108)115 (102, 117)
WHRA
F0.90 (0.85, 0.95)0.92 (0.84, 0.95)0.93 (0.91, 1.02)
M0.98 (0.95, 1.05)0.96 (0.92, 0.98)1.06 (1.04, 1.09)
Sub. – subjects; A – all study subjects (N=52); F – females (N=34); M – males (N=18); NGM – normal glucose metabolism subjects; IFG – impaired fasting glucose subjects; T2DM – type 2 diabetic subjects; FPG – fasting plasma glucose; FI – fasting insulin; HOMA-IR – homeostasis model assessment for insulin resistance; HbA1c – glycated hemoglobin; TC – total cholesterol; LDL-C – low-density lipoprotein cholesterol; HDL-C – high-density lipoprotein cholesterol; TG – triglycerides; BMI – body mass index; WHR – waist to hip ratio. (&) – Levels of FI and HbA1c were compared for patients untreated with drugs directly affecting fasting insulin levels (6 subjects were excluded from analysis). Significant differences in comparison to NGM group are denoted by (), while () marks differences among IFG and T2DM groups.
*/# ≤0.05;
** ≤0.01;
*** ≤0.001.
Waist circumference and WHR were not shown for group of all study participants as they are indicators strictly associated with sex.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750